Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07170995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
Started2025-10-22
View on ClinicalTrials.gov ↗

Amendment history

2025-11-14
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09→confirmed 2025-10-22
Study sitesdetails revised at 1 of 1 site
2025-09-11
Original filing
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.
Trial Details
NCT Number NCT07170995
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment 460 participants
Start Date 2025-10-22
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-18